Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of U.S. dollars ($)	Three Months Ended June 30, 2021						Six Months Ended June 30, 2021
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	215	$	215	$	—	$	439	$	439	$	—
License Fee – Over time	58		—		58		117		—		117
Total Drug Products	273		215		58		556		439		117
Concentrate Products
Product Sales – Point-in-time	14,379		13,026		1,353		29,084		26,227		2,857
License Fee – Over time	485		485		—		971		971		—
Total Concentrate Products	14,864		13,511		1,353		30,055		27,198		2,857
Net Revenue	$	15,137	$	13,726	$	1,411	$	30,611	$	27,637	$	2,974

In thousands of U.S. dollars ($)	Three Months Ended June 30, 2020						Six Months Ended June 30, 2020
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	182	$	182	$	—	$	381	$	381	$	—
License Fee – Over time	56		—		56		112		—		112
Total Drug Products	238		182		56		493		381		112
Concentrate Products
Product Sales – Point-in-time	15,168		13,319		1,849		30,280		26,826		3,454
License Fee – Over time	490		490		—		980		980		—
Total Concentrate Products	15,658		13,809		1,849		31,260		27,806		3,454
Net Revenue	$	15,896	$	13,991	$	1,905	$	31,753	$	28,187	$	3,566

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of U.S. dollars ($)	June 30, 2021		December 31, 2020
Receivables, which are included in "Trade and other receivables"	$	5,357	$	4,171
Contract liabilities	$	9,103	$	10,190